Format

Send to

Choose Destination
Trends Mol Med. 2013 Oct;19(10):633-42. doi: 10.1016/j.molmed.2013.08.002. Epub 2013 Sep 3.

Resistance to targeted therapies: a role for microRNAs?

Author information

1
IRCC, Institute for Cancer Research and Treatment at Candiolo, University of Torino, School of Medicine, 10060 Candiolo (Torino), Italy. Electronic address: cristina.migliore@ircc.it.

Abstract

The discovery of oncogene addiction dramatically changed the therapeutic approach for cancer treatment, and many drugs targeting specific molecular alterations are now in clinics. Despite the big success of these new compounds, the main limit to their efficacy is represented by resistance to therapy. The alteration of the activity or of the expression of many proteins has already been linked to the onset of resistance, but recent evidence indicates a role of microRNAs (miRNAs) as well. In this context, the idea of exploiting miRNAs as predictors of response or resistance to cancer therapy represents an intriguing possibility. The purpose of this review is to address the relationship between miRNAs and targeted therapies response and resistance.

KEYWORDS:

mechanisms of resistance; miRNAs; molecular therapies; sensitivity to therapy

PMID:
24012193
DOI:
10.1016/j.molmed.2013.08.002
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science Icon for University of Turin Instituional Repository AperTO
Loading ...
Support Center